Immix Biopharma (IMMX) said Tuesday that updated data for its drug NXC-201 showed a 94% overall response rate in patients with AL amyloidosis.
The drug had a complete response rate of 75% in the phase 1b/2 Nexicart-1 study, according to the company.
One patient maintained a complete response for 31.5 months, with ongoing remission as of Dec. 9, Immix added.
Shares of Immix were down 7.4% in recent trading.
Price: 2.25, Change: -0.29, Percent Change: -11.42
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。